Onderzoeker
Peter MESSIAEN
- Trefwoorden:Biomedische wetenschappen
- Disciplines:Immunologie niet elders geclassificeerd
Affiliaties
- Immunologie & Infectie (Departement)
Lid
Vanaf1 jan 2020 → Heden - Immunologie & Infectie (Onderzoeksgroep)
Lid
Vanaf1 jan 2020 → Heden - Limburg Clinical Research Center (Onderzoekscentrum)
Lid
Vanaf1 jan 2020 → Heden - Geneeskunde en Levenswetenschappen (Faculteit)
Lid
Vanaf1 feb 2015 → Heden - Biomedisch Onderzoeksinstituut (Onderzoeksinstituut)
Lid
Vanaf16 nov 2018 → 31 dec 2019 - Fysiologie - biochemie - immunologie (Departement)
Lid
Vanaf1 feb 2015 → 31 dec 2019 - Immunologie - Biochemie (Onderzoeksgroep)
Lid
Vanaf1 feb 2015 → 31 dec 2019
Projecten
1 - 1 of 1
- De relatie tussen beschermende versus beschadigende aspecten van de immuunreactie en de klinische uitkomst in het Limburgs COVID-19 cohortVanaf15 jun 2020 → 14 jun 2022Financiering: BOF - projecten
Publicaties
1 - 10 van 42
- Factors Associated with Health Care Providers' Preference for Forgoing an Oral Lead-In Phase When Initiating Long-Acting Injectable Cabotegravir and Rilpivirine in the SOLAR Clinical Trial(2023)
Auteurs: Tahilin Sanchez Karver, Miguel Pascual-Bernaldez, Alessandro Berni, Ahmed Hnoosh, Antonella Castagna, Peter MESSIAEN, Maria Jose Galindo Puerto, Mark Bloch, Eisuke Adachi, Gary Sinclair, et al.
Pagina's: 53 - 59 - Virulence Factor Genes in Invasive Escherichia coli Are Associated with Clinical Outcomes and Disease Severity in Patients with Sepsis: A Prospective Observational Cohort Study(2023)
Auteurs: Valentino D'ONOFRIO, Reinoud Cartuyvels, Peter MESSIAEN, Ivan Barisic, Inge GYSSENS
- Efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide for the treatment of HIV in a real-world setting in Belgium(2023)
Auteurs: Rakan Nasreddine, Eric Florence, Jean Cyr Yombi, Sophie Henrard, Gilles Darcis, Jens Van Praet, Linos D. Vandekerckhove, Sabine Allard, Remy Demeester, Peter MESSIAEN, et al.
Pagina's: 914 - 924 - Efficacy, durability, and tolerability of dolutegravir/lamivudine and dolutegravir/rilpivirine for the treatment of HIV in a real-world setting in Belgium(2023)
Auteurs: Rakan Nasreddine, Jean Cyr Yombi, Gilles Darcis, Eric Florence, Sabine D. Allard, Marie-Angelique De Scheerder, Sophie Henrard, Remy Demeester, Peter MESSIAEN, Nathalie Ausselet, et al.
Pagina's: 267 - 278 - Dynamics of Weight Change After Initiation of Contemporaneous Antiretroviral Therapy in Treatment-Naive HIV-1 Infected Patients: Results From the Belgian HIV Cohort 2015-2021(2023)
Auteurs: Jens T. Van Praet, Ben Serrien, Nathalie Ausselet, Gilles Darcis, Remy Demeester, Paul De Munter, Marie-Angelique De Scheerder, Jean-Christophe Goffard, Agnes Libois, Peter MESSIAEN, et al.
Pagina's: E4 - E6 - Continuum of HIV care by key populations in Belgium: Cross-sectional and longitudinal views(2023)
Auteurs: D. Van Beckhoven, B. Serrien, G. Darcis, R. Demeester, P. De Munter, S. Henrard, A. Libois, Peter MESSIAEN, J. Van Praet, J. Macq
Pagina's: 224 - 226 - Comprehensive antibody and cytokine profiling in hospitalized COVID-19 patients in relation to clinical outcomes in a large Belgian cohort(2023)
Auteurs: Pieter RUYTINX, Patrick VANDORMAEL, Judith FRAUSSEN, Zoe PIETERS, Stef Thonissen, Niels HELLINGS, Piet STINISSEN, Ina CALLEBAUT, Joris PENDERS, Karolien VANHOVE, et al.
- Subjective sleep quality evolution in patients starting or switching to dolutegravir or cabotegravir: A real-world longitudinal study(2023)
Auteurs: Peter MESSIAEN, E. Van Steenkiste, J. Reumers, Janneke COX, K. van Halem, Jeroen VAN DER HILST
Pagina's: 591 - 592 - SOLAR 12-month European results: Randomized switch trial of CAB plus RPV vs. oral BIC/FTC/TAF(2023)
Auteurs: I. De Los Santos Gil, A. Ustianowski, G. Orofino, S. Scholten, Peter MESSIAEN, F. Maggiolo, D. Braun, C. Wyen, R. Demeester, C. Jacomet, et al.
Pagina's: 204 - 206 - Mental health impact of COVID-19 in frontline healthcare workers in a Belgian Tertiary care hospital: a prospective longitudinal study(2022)
Auteurs: Shauni Gilis, Peter MESSIAEN, Jessie Schoofs, Eveline Van Steenkiste
Pagina's: 533 - 540